Therefore, we propose to use the flexibility of UbcH10 in the diagnosis and treatment of NSCLC in fact, while the higher expression levels of UbcH10 might represent an early marker of developing resistance in patients treated with TKI, at the same time, the lower expression of UbcH10 could likely indicate the presence of EGFR mutations. This evidence concerns the gene UBE2C and non-small cell lung carcinoma.